开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

未开盘 03-28 16:08:43

7.470

-0.390

-4.96%

最高7.900	最低7.450	成交量266.90万
今开7.900	昨收7.860	日振幅5.73%
总市值33.43亿	流通市值33.43亿	总股本4.47亿
成交额2,012万	换手率0.60%	流通股本4.47亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":7.47,"timestamp":1679990923020,"preClose":7.86,"halted":0,"volume":2669000,"delay":0,"floatShares":447499600,"shares":447499600,"eps":-2.6970394,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.39,"latestTime":"03-28 16:08:43","open":7.9,"high":7.9,"low":7.45,"amount":20121095,"amplitude":0.057252,"askPrice":7.47,"askSize":8500,"bidPrice":7.46,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-3.237534684867848,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1680053400000},"adr":0,"listingDate":1590076800000,"adjPreClose":7.86,"volumeRatio":1.193133,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2322263567","title":"左手福瑞他恩右手AR-PROTAC，开拓药业（9939.HK）手握“王炸”掘金百亿脱发赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2322263567","media":"权证网","top":-1,"share":"https://www.laohu8.com/m/news/2322263567?lang=zh_CN&edition=full","pubTime":"2023-03-28 21:07","pubTimestamp":1680008879,"startTime":"0","endTime":"0","summary":"2023年3月28日，开拓药业发布公告称其自主研发、潜在全球同类首创的福瑞他恩治疗男性雄激素性脱发的中国注册性III期临床试验已于近期完成全部受试者入组。开拓药业表示，预计2023年第四季度公布该III期临床试验的顶线数据。·福瑞他恩均显示出良好的安全性。除了福瑞他恩，开拓药业皮科管线中还有一款治疗雄激素性脱发的产品GT20029。手握福瑞他恩和GT20029两款“王炸”产品，开拓药业正在撬动脱发治疗药物这一百亿级别的广阔蓝海市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230328210800827226e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230328210800827226e5&s=b","is_publish_highlight":false},{"id":"2322268239","title":"开拓药业-B(09939)：福瑞他恩治疗男性雄激素性脱发中国III期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2322268239","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2322268239?lang=zh_CN&edition=full","pubTime":"2023-03-28 20:55","pubTimestamp":1680008117,"startTime":"0","endTime":"0","summary":"开拓药业-B(09939)发布公告，公司自主研发、潜在全球同类首创的候选药物福瑞他...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_14.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_14.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/900696.html","is_publish_highlight":false},{"id":"2322268467","title":"开拓药业-B(09939)公布普克鲁胺前列腺癌单药III期临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2322268467","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2322268467?lang=zh_CN&edition=full","pubTime":"2023-03-28 20:50","pubTimestamp":1680007803,"startTime":"0","endTime":"0","summary":"智通财经APP讯，开拓药业-B 发布公告，该公司开发普克鲁胺针对转移性去势抵抗性前列腺癌在中国开展多中心、随机、双盲、安慰剂对照的III期临床试验，旨在评估普克鲁胺对接受阿比特龙及多西他赛治疗后或对其不耐受的mCRPC患者的疗效及安全性。截至本公告日期，单药III期临床试验已完成OS事件的数据收集、分析及总结。公司将继续分析普克鲁胺单药III期临床试验的结果，并计划将研究结果发表在同行评审的学术期刊上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/900687.html","is_publish_highlight":false},{"id":"2322684832","title":"诺德基金经理朱明睿：今年有望成为医药板块反攻的一年 关注消费医疗、创新器械、中药等赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2322684832","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2322684832?lang=zh_CN&edition=full","pubTime":"2023-03-28 20:28","pubTimestamp":1680006539,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近期，诺德基金经理朱明睿发表观点称，今年有望成为医药板块反攻的一年。朱明睿表示，医药板块下跌空间比较有限，前期各方面负面因素的扰动已基本在估值上得到反馈。从细分板块角度分析，朱明睿当前比较看好医药板块的消费医疗、创新器械以及药品赛道中的中药、仿制药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/900653.html","is_publish_highlight":false},{"id":"2322241259","title":"国家医保局：新冠治疗药品价格实施分类管理 A类优先采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2322241259","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2322241259?lang=zh_CN&edition=full","pubTime":"2023-03-28 18:46","pubTimestamp":1680000392,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月28日，国家医疗保障局办公室发布关于《关于完善新冠治疗药品价格形成机制实施分类管理的通知》。A 类药品，是指按照《指引》进行首发报价或评估调整，疗程治疗费用与医保药品目录内同类药品差异较小的新冠治疗药品。新冠治疗药品供求形势、价格走势等出现重大变化的，医保部门适时研究调整参照基准和比价系数。正式纳入医保药品目录前，所有新冠治疗药品按《指引》持续开展评估调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/900450.html","is_publish_highlight":false},{"id":"2322542152","title":"白云山(00874.HK)：广州医药完成发行2023年度第一期超短期融资券","url":"https://stock-news.laohu8.com/highlight/detail?id=2322542152","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2322542152?lang=zh_CN&edition=full","pubTime":"2023-03-28 18:43","pubTimestamp":1680000198,"startTime":"0","endTime":"0","summary":"格隆汇3月28日丨白云山(00874.HK)公布，2023年3月24日，公司控股子公司广州医药发行了2023年度第一期超短期融资券，实际发行总额人民币3亿元，发行利率2.59%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2023/03/28184337434686.shtml","is_publish_highlight":false},{"id":"2322025957","title":"白云山(00874)：广州医药完成发行3亿元超短期融资券","url":"https://stock-news.laohu8.com/highlight/detail?id=2322025957","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2322025957?lang=zh_CN&edition=full","pubTime":"2023-03-28 18:40","pubTimestamp":1680000006,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)公布，2023年3月24日，广州医药发行了2023年度第一期超短期融资券，实际发行总额3亿元，期限270日，发行利率为2.59%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/900453.html","is_publish_highlight":false},{"id":"2322723716","title":"本立科技：公司从事医药中间体、农药中间体、及新材料中间体的研发、生产和销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2322723716","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2322723716?lang=zh_CN&edition=full","pubTime":"2023-03-28 16:50","pubTimestamp":1679993452,"startTime":"0","endTime":"0","summary":"公司从事医药中间体、农药中间体、及新材料中间体的研发、生产和销售。公司目前暂无光刻胶领域相关产品。本立科技主营业务：医药中间体、农药中间体、新材料中间体的研发、生产和销售。以上内容由证券之星根据公开信息整理，与本站立场无关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032800026655.shtml","is_publish_highlight":false},{"id":"2322364233","title":"长药控股：公司增加的应收账款主要来自医药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2322364233","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2322364233?lang=zh_CN&edition=full","pubTime":"2023-03-28 13:58","pubTimestamp":1679983088,"startTime":"0","endTime":"0","summary":"长药控股03月28日在投资者关系平台上答复了投资者关心的问题。投资者：公司应收账款从2020年9月的3.74亿，暴增至2022年的14.73亿。根据近五年财报数据，证券之星估值分析工具显示，长药控股行业内竞争力的护城河一般，盈利能力较差，营收成长性一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032800019393.shtml","is_publish_highlight":false},{"id":"2322286277","title":"开拓药业-B盘中异动 大幅跳水5.23%报7.450港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2322286277","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2322286277?lang=zh_CN&edition=full","pubTime":"2023-03-28 10:34","pubTimestamp":1679970841,"startTime":"0","endTime":"0","summary":"2023年03月28日早盘10时34分，开拓药业-B股票出现异动，股价大幅跳水5.23%。截至发稿，该股报7.450港元/股，成交量139.2万股，换手率0.31%，振幅5.73%。资金方面，该股资金流入210.037万港元，流出735.668万港元。其相关个股中，顺腾国际控股、华控康泰、朗生医药涨幅较大，振幅较大的相关个股有顺腾国际控股、朗生医药、联康生物科技集团，振幅分别为45.95%、17.28%、16.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023032810340282be8685&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023032810340282be8685&s=b","is_publish_highlight":false},{"id":"2322283902","title":"孚诺医药终止创业板IPO 保荐机构为海通证券","url":"https://stock-news.laohu8.com/highlight/detail?id=2322283902","media":"媒体滚动","top":-1,"share":"https://www.laohu8.com/m/news/2322283902?lang=zh_CN&edition=full","pubTime":"2023-03-28 09:51","pubTimestamp":1679968260,"startTime":"0","endTime":"0","summary":"　　中国经济网北京3月28日讯据深交所网站昨日消息，深交所决定终止对浙江孚诺医药股份有限公司首次公开发行股票并在创业板上市的审核。　　孚诺医药是一家专注于皮肤外用化学药的研发、生产及销售的国家级高新技术企业。傅龙云通过孚诺投资和日升昌投资间接控制公司66.90%的股份，为公司实际控制人。　　孚诺医药的保荐机构是海通证券，保荐代表人是刘裕俊、陈亚聪。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2023-03-28/doc-imynktue1522880.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2023-03-28/doc-imynktue1522880.shtml","is_publish_highlight":false},{"id":"2322426467","title":"离职的基金经理们，去向定了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2322426467","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2322426467?lang=zh_CN&edition=full","pubTime":"2023-03-27 19:41","pubTimestamp":1679917277,"startTime":"0","endTime":"0","summary":"高楠、蔡宇滨、何以广...","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/c72d911c-bd70-4d33-8d34-13cf32c82733.jpeg?imageView2/1/w/340/h/340","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/c72d911c-bd70-4d33-8d34-13cf32c82733.jpeg?imageView2/1/w/340/h/340"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3685009","is_publish_highlight":false},{"id":"2322447383","title":"“超级牛散”赵建平关联人最新买进这只股！此前布局这家同类公司股价刚刚创新高，或爆赚2300万……","url":"https://stock-news.laohu8.com/highlight/detail?id=2322447383","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2322447383?lang=zh_CN&edition=full","pubTime":"2023-03-27 18:59","pubTimestamp":1679914740,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　作为一个神秘的投资群体，牛散们手握重金，风格各有不同。本期的“主角”赵吉就是一位“标签”极其鲜明的投资人，其尤其偏爱刚刚上市不久的次新股，从赵吉此前布局的次新标的来看，有不少在其入驻之后都迎来了大涨。　　近日，一家次新医药股披露的最新一期股东持仓中，赵吉以新进姿态现身其中。那么，被其最新“相中”的这只医药股，机会如何呢？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2023-03-27/doc-imynifsz4798108.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2023-03-27/doc-imynifsz4798108.shtml","is_publish_highlight":false},{"id":"2322420904","title":"孚诺医药等3家公司深交所IPO状态变更为“终止(撤回)”","url":"https://stock-news.laohu8.com/highlight/detail?id=2322420904","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2322420904?lang=zh_CN&edition=full","pubTime":"2023-03-27 18:48","pubTimestamp":1679914080,"startTime":"0","endTime":"0","summary":"3月27日，孚诺医药、芯德科技、爱得科技共3家公司深交所IPO状态变更为“终止(撤回)”。\n\n炒股开户享福利，送投顾服务60天体验权，一对一指导服务！\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/hkstocknews/2023-03-27/doc-imynifsx8622376.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkstocknews/2023-03-27/doc-imynifsx8622376.shtml","is_publish_highlight":false},{"id":"2322644572","title":"圣泉集团(605589.SH)控股子公司尚博医药拟申请在新三板挂牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2322644572","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2322644572?lang=zh_CN&edition=full","pubTime":"2023-03-27 17:14","pubTimestamp":1679908463,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣泉集团(605589.SH)发布公告，公司控股子公司济南尚博医药股份有限公司(简称“尚博医药”)拟申请在全国中小企业股份转让系统(“新三板”)挂牌并公开转让。尚博医药主要致力于为国内外制药企业及医药研发机构提供医药中间体等的定制研发、工艺开发和生产制造等服务。尚博医药是在新三板挂牌后，仍是公司合并报表范围内控股子公司，不会影响公司对尚博医药的控制权，不会影响公司独立上市地位，不会对公司的财务状况、经营成果及持续经营构成重大影响。尚博医药在新三板挂牌，有利于公司整体效益最大化，符合公司的长期发展战略。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/899274.html","is_publish_highlight":false},{"id":"2322439604","title":"港股收盘(3.27)|恒指跌1.75% 互联网、中特估概念等领跌 部分医药医疗股飘红","url":"https://stock-news.laohu8.com/highlight/detail?id=2322439604","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2322439604?lang=zh_CN&edition=full","pubTime":"2023-03-27 16:35","pubTimestamp":1679906143,"startTime":"0","endTime":"0","summary":"大盘明显调整，主要股指回撤至5日均线附近。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20230327/20230327164554_36225.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20230327/20230327164554_36225.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/899224.html","is_publish_highlight":false},{"id":"2322142504","title":"华泰证券：A股或行至中局 伏击热点扩散的电子、医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2322142504","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2322142504?lang=zh_CN&edition=full","pubTime":"2023-03-27 13:32","pubTimestamp":1679895124,"startTime":"0","endTime":"0","summary":"Q2日历效应虽转弱，但库存周期才是胜负手。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20230327/20230327133349_15288.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20230327/20230327133349_15288.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/899037.html","is_publish_highlight":false},{"id":"2322725151","title":"英伟达、华为等巨头争相入局AI医药！这些上市公司布局相关业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2322725151","media":"财联社 旭日","top":-1,"share":"https://www.laohu8.com/m/news/2322725151?lang=zh_CN&edition=full","pubTime":"2023-03-25 17:40","pubTimestamp":1679737200,"startTime":"0","endTime":"0","summary":"英伟达与全球100多家医疗保健企业就Clara模型合作，还携手日本三井英打造能发现药物的AI项目Tokyo-1，百度文心一言发布首个落地医药行业的产品GBI-Bot，华为云盘古药物分子大模型辅助新药研发，梳理布局相关业务的A股上市公司名单（附图）。","market":"sh","thumbnail":"https://img.cls.cn/images/20230324/1zdk5v5NC1.jpg","type":0,"news_type":0,"thumbnails":["https://img.cls.cn/images/20230324/1zdk5v5NC1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.chinastarmarket.cn/detail/1303650","is_publish_highlight":false},{"id":"2321919927","title":"桂林三金：3月23日接受机构调研，平安证券医药、观富资产参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2321919927","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2321919927?lang=zh_CN&edition=full","pubTime":"2023-03-24 18:12","pubTimestamp":1679652761,"startTime":"0","endTime":"0","summary":"2023年3月24日桂林三金发布公告称公司于2023年3月23日接受机构调研，平安证券医药、观富资产参与。公司第一期员工持股计划确认的管理费用在当期不得抵扣造成所得税费用增大。桂林三金主营业务：中成药的研发、制造与销售。根据近五年财报数据，证券之星估值分析工具显示，桂林三金行业内竞争力的护城河一般，盈利能力一般，营收成长性较差。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032400030077.shtml","is_publish_highlight":false},{"id":"2321199667","title":"推动行业前行的力量｜以岭药业荣膺医学家年会“十大医药先锋企业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2321199667","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2321199667?lang=zh_CN&edition=full","pubTime":"2023-03-24 17:59","pubTimestamp":1679651977,"startTime":"0","endTime":"0","summary":"以岭药业荣获2022年度“推动行业前行的力量·十大医药先锋企业”称号。以岭药业围绕络病理论研究，先后承担和完成了国家973、863等国家级重大项目40余项，取得国内外专利800余项，荣获国家级大奖6项。多年来，以岭药业不断发挥中药头部企业的引领作用，利用现代科学技术与传统中医药相结合，研发出系列创新中药，结出累累硕果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.stockstar.com/SS2023032400029665.shtml","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.02},{"period":"1month","weight":-0.1603},{"period":"3month","weight":-0.2776},{"period":"6month","weight":-0.3069},{"period":"1year","weight":-0.3007},{"period":"ytd","weight":-0.202}],"websiteUrl":"http://www.kintor.com.cn","compareEarnings":[{"period":"1week","weight":0.0298},{"period":"1month","weight":-0.0221},{"period":"3month","weight":-0.0013},{"period":"6month","weight":0.1343},{"period":"1year","weight":-0.0858},{"period":"ytd","weight":-0.0108}],"name":"开拓药业-B","description":"开拓药业有限公司是一家临床阶段新药开发商，专注于研究癌症药物及其他雄激素受体（AR）相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌（mCRPC）的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。","exchange":"SEHK","nameEN":"KINTOR PHARMA-B","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.12.1","shortVersion":"4.12.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}